check_circleStudy Completed

Pulmonary Arterial Hypertension

A study to learn about how well riociguat works, how safe it is and how it is used under real world conditions in patients in the United States who are receiving riociguat for high blood pressure in the arteries that carry blood from the heart to the lungs (pulmonary arterial hypertension, PAH)

Trial purpose

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that carry blood from the heart to the lungs. PAH occurs when the openings in the blood vessels of the lungs get smaller and smaller. These smaller openings can be caused by the following:
- The walls of the arteries tightening
- The walls of the arteries becoming stiff and narrow from an overgrowth of cells
The increased pressure in the pulmonary arteries strains the right side of the heart and it begins to fail, causing difficulty breathing and other symptoms. As PAH progresses, symptoms get worse.
There is no cure for PAH, but several medications like endothelin receptor antagonists (ERAs), prostacyclin analogues (PCAs) and riociguat, a soluable guanylate cyclase stimulator, are available to help slow the progression of changes in the pulmonary arteries and help reduce symptoms. Riociguat can be taken together with ERAs and PCAs.
In this study, the researchers want to learn about how well riociguat works, how safe it is when patients take it in 1 of these ways:
- alone
- with ERA
- with PCA
- with ERA and PCA
The dosage for each patient will be decided by their doctor.
The researchers will review information collected from the patients who have decided with their doctor to start riociguat treatment for their PAH. The study will include about 500 patients in the United States who are at least 18 years old. All of the patients will have either just started taking riociguat or will have been taking it for less than 3 months
No investigational products will be administered in this study. Patients will be treated with the Standard of Care (SOC) for PAH. The SOC is the currently appropriate treatment in accordance with scientific evidence and agreed upon in collaboration between medical experts for PAH. There will be no study-mandated visits or treatments.
The patients will be in the study for up to 2 years. During this time, they will visit their doctor every 3 to 6 months as part of the Standard of Care. At these visits, the patients will answer questions about their PAH symptoms and whether they have any medical problems. They will also do exercise tests to see how well they are able to breathe and how tired they get while exercising. The doctors will perform other usual examinations which are part of the Standard of Care such as echocardiograms (images of the heart to show how the heart is working) and a right heart catheters (to measure the pressures in the heart) and will take the usual blood and urine samples.

Key Participants Requirements

Sex

All

Age

18 - N/A (No Limit)

Trial summary

Enrollment Goal
500
Trial Dates
July 2021 - February 2025
Phase
Phase IV
Could I Receive a placebo
No
Products
Riociguat, BAY 632521
Accepts Healthy Volunteer
No

Primary Outcome

  • Incidence of adverse events (AEs) and serious adverse events (SAEs)
    date_rangeTime Frame:
    Up to 24 months
  • Change of 6-minute walk distance (6MWD) from baseline to Months 6, 12, and 24
    date_rangeTime Frame:
    At baseline, Month 6, 12, and 24
  • Change of NT-proBNP from baseline to Months 6, 12, and 24
    NT-proBNP: N-terminal pro-hormone B-type natriuretic peptide
    date_rangeTime Frame:
    At baseline, Month 6, 12, and 24
  • Change of BNP from baseline to Months 6, 12, and 24
    BNP: B-type natriuretic peptide
    date_rangeTime Frame:
    At baseline, Month 6, 12, and 24
  • Change of clinical PAH scores from baseline to Months 6, 12, and 24
    date_rangeTime Frame:
    At baseline, Month 6, 12, and 24
  • Change of hemodynamic measurements from RHC from baseline to Months 6, 12, and 24
    RHC: Right-heart catheterization
    date_rangeTime Frame:
    At baseline, Month 6, 12, and 24
  • Change of ECHO measurements from baseline to Months 6, 12, and 24
    ECHO: Echocardiogram
    date_rangeTime Frame:
    At baseline, Month 6, 12, and 24
  • Change of laboratory tests from baseline to Months 6, 12, and 24
    date_rangeTime Frame:
    At baseline, Month 6, 12, and 24
  • Change of NYHA/WHO PH functional class from baseline to Months 6, 12, and 24
    NYHA: New York Heart Association WHO: World Health Organization
    date_rangeTime Frame:
    At baseline, Month 6, 12, and 24

Secondary Outcome

  • Change from baseline to Month 6 and change from baseline to Month 12 in Borg Dysponea Index
    date_rangeTime Frame:
    At baseline, Month 6 and Month 12
  • Change from baseline to Month 6 and change from baseline to Month 12 in emPHasis-10
    date_rangeTime Frame:
    At baseline, Month 6 and Month 12
  • Persistence/discontinuation rates for riociguat
    date_rangeTime Frame:
    Up to 24 months
  • Reasons for discontinuation of riociguat
    date_rangeTime Frame:
    At Month 6, 12, and 24 post-baseline
  • Real-world treatment patterns for riociguat for PAH
    date_rangeTime Frame:
    Up to 24 months
  • Demographic of patients treated with riociguat
    date_rangeTime Frame:
    Up to 24 months
  • Clinical characteristics of patients treated with riociguat
    date_rangeTime Frame:
    Up to 24 months

Trial design

RiOciguAt UseRs Registry– The ROAR registry
Trial Type
Observational
Intervention Type
Drug
Trial Purpose
N/A
Allocation
N/A
Blinding
Open Label
Assignment
N/A
Trial Arms
N/A